1. Home
  2. KMDA vs ASMB Comparison

KMDA vs ASMB Comparison

Compare KMDA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$8.09

Market Cap

488.6M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$26.16

Market Cap

442.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMDA
ASMB
Founded
1990
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
488.6M
442.9M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
KMDA
ASMB
Price
$8.09
$26.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$44.20
AVG Volume (30 Days)
34.7K
91.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.94
N/A
Revenue Next Year
$9.84
$638.39
P/E Ratio
$24.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.50
$11.42
52 Week High
$9.35
$39.71

Technical Indicators

Market Signals
Indicator
KMDA
ASMB
Relative Strength Index (RSI) 42.91 37.61
Support Level $7.96 $23.19
Resistance Level $8.40 $27.14
Average True Range (ATR) 0.17 1.44
MACD -0.01 -0.28
Stochastic Oscillator 11.75 1.47

Price Performance

Historical Comparison
KMDA
ASMB

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: